Newsroom | Co-Diagnostics, Inc.

Press Releases

Newsroom

Press Releases

In the News

Media Resources

Feb 26, 2019

Co-Diagnostics, Inc. Completes Submission of CE Mark Registration for Zika/Dengue/Chikungunya Multiplex Test

Company’s multiplexed Logix Smart™ ZDC Test to be available for purchase with CE mark in March 2019

Salt Lake City, Utah – February 26, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic...
Feb 22, 2019

Co-Diagnostics, Inc. Regains Compliance with NASDAQ Listing Standards

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
Feb 21, 2019

Co-Diagnostics, Inc. Announces Mosquito Vector Control Training Course in the Dominican Republic

Trainings will be conducted for staff and customers of Laboratorios Franja, including demonstrations of Company’s vector control products

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
Feb 4, 2019

Co-Diagnostics, Inc. Announces Closing of $5.5 Million Registered Direct Offering

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today...
Jan 30, 2019

Co-Diagnostics, Inc. Announces Elimination of Debt, Additional Capital Infusion

Transaction included $3M of preferred shares, and the elimination of $2M of debt

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
Jan 30, 2019

Co-Diagnostics, Inc. Announces $5.5 Million Registered Direct Offering

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today...
Jan 23, 2019

Co-Diagnostics, Inc. CoPrimer™ Platform Featured at PAG XXVII Conference

Presentation coincided with launch of a private-label CoPrimer Product

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
Jan 10, 2019

Co-Diagnostics, Inc to Present at PAG XXVII on January 14 in San Diego

Company Senior Research Scientist will be a guest speaker of LGC, Biosearch

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
Dec 14, 2018

Co-Diagnostics, Inc Expands Licensing Opportunities Internationally with Receipt of UK Patent for RapidProbe™ Technology

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
Nov 30, 2018

Co-Diagnostics CEO to Discuss Progress and Forecasts in a Lytham Partners’ Virtual Investors Conference Presentation on Tuesday, December 4, 2018 at 4:00 pm ET

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
Nov 26, 2018

Co-Diagnostics, Inc. to Conduct Product Training Seminars with Distributor and Customers in the Dominican Republic

Trainings will be conducted for staff and customers of Laboratorios Franja, followed by launch of Company’s products in DR

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
Oct 30, 2018

Co-Diagnostics, Inc. and LGC, Biosearch Technologies Sign License Agreement for CoPrimer Technology

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, and...
Oct 29, 2018

Co-Diagnostics, Inc. to Present at Utah Mosquito Abatement Association Conference

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, and...
Oct 18, 2018

Co-Diagnostics, Inc. Receives CE Mark for Zika Screening Test

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
Oct 9, 2018

Co-Diagnostics Receives Patent for CoPrimer™ Technology

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
Sep 20, 2018

Co-Diagnostics, Inc. to Present at the Fourth Annual Robins Equity Research Roundup

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
Sep 13, 2018

Co-Diagnostics Adds Central and South America to its List of International Target Markets

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
Aug 21, 2018

Co-Diagnostics Announces Filing of S-3 Shelf Registration

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
Aug 10, 2018

Co-Diagnostics Announces Closing of Debt Financing

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
Jul 25, 2018

Co-Diagnostics Receives CE Mark for Tuberculosis Test Kit

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
Jul 17, 2018

Co-Diagnostics Completes Submission of CE Mark Registration for Tuberculosis Screening Test

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests,...
Jun 11, 2018

Co-Diagnostics, Inc. to Host Booth at CARPHA Conference

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the...
Jun 5, 2018

Co-Diagnostics, Inc. Announces Advancement of CoPrimers™ Technology in Multiplex SNP Genotyping

Proof of concept study successful in demonstrating potential SNP multiplexing applications

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the...
Jun 1, 2018

Co-Diagnostics, Inc. Announces Participation in Research Project with Stanford University

CoPrimers™ used in proof of concept evaluation

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today that...
Apr 16, 2018

Co-Diagnostics CEO to Discuss Strategic Direction in a Lytham Partners’ Virtual Presentation and Fireside Chat Event on Thursday, April 19, 2018 at 2:00 pm ET

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostic testing, announced...
Apr 6, 2018

Co-Diagnostics Files Initial Annual Report on Form 10-K and Updates Corporate Developments

CODX updates on initial six months as a public company

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced the...
Mar 22, 2018

Co-Diagnostics, Inc. Announces Construction Update at JV Manufacturing Facility in India

Project moving forward on schedule, with production to begin in Q3 2018

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today an...
Feb 28, 2018

Co-Diagnostics Inc Announces Positive Results from CoPrimers™ Technology in Multiplex Tests for SNP Detection

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the...
Feb 21, 2018

Co-Diagnostics, Inc. Ships Product to India for Validation Study

Shipment includes 10,000 tests to be sold as Research Use Only by Joint Venture

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Jan 30, 2018

Co-Diagnostics, Inc. Initiates Vector Control Program in Dominican Republic

Program received enthusiastically by regional Ministries of Health

SALT LAKE CITY–(BUSINESS WIRE)– Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced...
Dec 19, 2017

Co-Diagnostics, Inc. Enters Into Lease for New, Upgraded Laboratory Facility

Laboratory will meet CGMP Requirements of FDA; Will be BSL-2 to allow enhanced in-house verification and validation activities

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today...
Dec 12, 2017

Co-Diagnostics, Inc. Announces Sale of Molecular Diagnostic Tests, Including Zika Virus, to Major Caribbean Laboratory

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Nov 15, 2017

Co-Diagnostics, Inc. Reports Q3 Financial Results and Updates Corporate Developments

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Nov 7, 2017

Co-Diagnostics, Inc. Manufacturing Joint Venture Breaks Ground in India

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, and...
Nov 2, 2017

Co-Diagnostics, Inc. Granted ISO 13485:2016 Certification

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, has been...
Oct 31, 2017

Co-Diagnostics, Inc. Products to Be Presented at Fair of Havana 2017

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Oct 16, 2017

Co-Diagnostics, Inc. to Present Zika Tests to Dominican Republic Ministry of Health

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Sep 25, 2017

Co-Diagnostics, Inc. to Present at Robins Equity Research Roundup 2017

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Sep 7, 2017

Co-Diagnostics, Inc. to Present at NewsMakers Conference 2017

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Sep 5, 2017

Co-Diagnostics, Inc. to Sign Purchase Agreement with MEDCIS Pathlabs

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, and MEDCIS...
Aug 24, 2017

Co-Diagnostics, Inc. Strengthens Zika Customer Base in Caribbean Basin

Sales expected upon successful performance evaluation and validation

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Aug 21, 2017

Co-Diagnostics, Inc. CEO to Present at 2017 SALSS

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Aug 10, 2017

Co-Diagnostics, Inc. to Undergo ISO 13485:2016 Audit

Audit to prepare for eventual sales into the US market

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, will be...
Aug 2, 2017

Co-Diagnostics, Inc. to Attend AACC 2017

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, will be...
Jul 27, 2017

Co-Diagnostics, Inc. Verifies Zika CoPrimer™ Test

SALT LAKE CITY, July 27, 2017 (GLOBE NEWSWIRE) — Co-Diagnostics, Inc. (NASDAQ:CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has a unique, proprietary...
Jul 25, 2017

Co-Diagnostics, Inc. Announces Joint Venture in India

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, officially...
Jul 17, 2017

Co-Diagnostics, Inc. to Use IPO Proceeds to Expand Operations

Sandy, UT – July 17, 2017 – Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the...
Jul 12, 2017

Co-Diagnostics, Inc. Announces Pricing of IPO

Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic...

Show per page

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.

Click here to learn more

Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States

1 (801) 438-1036

info@codiagnostics.com

COMPANY

Site Terms and Conditions